Todos os estudos
RecrutamentoOBSERVACIONAL

Maternal and Postnatal Outcomes Study (MOS): A Global Observational Registry Assessing the Safety of Elfabrio® in Women With Fabry Disease and Their Infants During Pregnancy and Breastfeeding

This study, called the Maternal and Postnatal Outcomes Study (MOS), is looking into the safety of a medicine called Elfabrio for women with Fabry disease. It focuses on women who have used Elfabrio within 30 days before pregnancy or during pregnancy and breastfeeding. Researchers want to see how these pregnancies turn out for both the mothers and their babies. They'll be checking for any health problems in the mothers and any birth defects or other issues in the newborns. It's an observation study, meaning no new treatments are given; it just collects information over 10 years to understand the real-world effects.

Em resumo

Status
Recrutamento
Patrocinador
Chiesi Farmaceutici S.p.A.
Meta de inscrição
10
Iniciar
23 May 2025
Conclusão estimada
01 Dec 2034

Sobre o que é este estudo?

If you are a woman with Fabry disease and are pregnant or thinking about getting pregnant, this study might be of interest to you. It's called the Maternal and Postnatal Outcomes Study (MOS) and it aims to understand how safe a medicine called Elfabrio is for expectant mothers and their babies. Doctors want to learn if using Elfabrio shortly before or during pregnancy, or while breastfeeding, has any effects on the mother's health, the pregnancy itself, or the baby's development.

This study is important because it will help doctors and patients make better decisions about treatment for Fabry disease during such a crucial time. It's not a study where you'll be given a new drug or told to change your current treatment. Instead, it's an 'observational' study. This means it simply collects information about what naturally happens to women with Fabry disease who are using or have used Elfabrio around the time of pregnancy and breastfeeding.

The study will follow women and their babies for a long time – up to 12 months after the baby is born. Researchers will look at things like how healthy the mother is, any problems during pregnancy, how the birth goes, and the baby's health in their first year, including checking for any birth defects.

Pontos principais

  • This study focuses on women with Fabry disease taking Elfabrio during pregnancy or breastfeeding.
  • It aims to understand the safety and outcomes for both mothers and their babies.
  • It is an 'observational' study, meaning no changes to your current treatment.
  • Information will be collected securely online for up to 12 months after birth.
  • Insights gained will help improve care for future patients.
  • You can withdraw at any time without affecting your medical care.

Quem pode ser elegível?

You might be able to take part in this study if you are a woman with Fabry disease and have received the medicine Elfabrio. This includes if you had Elfabrio within 30 days before getting pregnant, or at any point during your pregnancy or while you were breastfeeding.

Your baby would also be part of the study. There are no other health reasons that would stop you from joining this study. You (or your parent/guardian if you cannot legally consent yourself) would need to be able to understand and sign a consent form.

Este estudo pode ser adequado para você?

Responda a estas perguntas rápidas para ver se você pode ser elegível. Este é apenas um guia — a decisão final é da equipe de pesquisa.

  1. I am a woman with Fabry disease.
  2. I have taken Elfabrio within 30 days before conception, or during pregnancy, or while breastfeeding.
  3. I (or my legal guardian) can understand and sign a consent form.
  4. My baby is also part of the study.
  5. I am comfortable with my medical information being collected for research.
Responda a todas as perguntas para ver o seu resultado.

O que envolve a participação?

If you decide to take part, you or your doctor will share information about your health and your pregnancy. This information will be put into a secure online system. This can be done either during your pregnancy or after your baby is born. The researchers will collect details about your pregnancy and your baby's health from the time you enrol until your baby is 12 months old. This study is observational, meaning it won't change any of your current medical care or treatment decisions; doctors will continue to treat you as they normally would.

Riscos e benefícios potenciais

There are no direct medical benefits for you or your baby from participating in this study, as it doesn't involve new treatments. However, the information gathered will help future patients and doctors understand more about Fabry disease and Elfabrio during pregnancy and breastfeeding. There are no direct physical risks as no experimental treatments are given. Your medical information will be kept private and secure. You are free to withdraw from the study at any time without affecting your medical care.

Localizações (5)

  • No physical study sites - Decentralized, web-based registry
    Código postal verificado
    Washington D.C., Estados Unidos· Recrutamento
  • No physical study sites - Decentralized, web-based registry
    Código postal verificado
    Berlim, Alemanha· Recrutamento
  • No physical study sites - Decentralized, web-based registry
    Código postal verificado
    Roma, Itália· Recrutamento
  • No physical study sites - Decentralized, web-based registry
    Código postal verificado
    Madrid, Espanha· Recrutamento
  • No physical study sites - Decentralized, web-based registry
    Código postal verificado
    Londres, Reino Unido· Ainda não recrutando

Perguntas frequentes

What is Fabry disease?

Fabry disease is a rare genetic condition that can affect many parts of the body, causing a range of symptoms.

What is Elfabrio?

Elfabrio is a medicine used to treat Fabry disease. This study is specifically looking at its use around pregnancy and breastfeeding.

Will I get new medicine if I join this study?

No, this is an observational study. You will continue with your usual medical care and any medicines prescribed by your doctor.

Por quanto tempo estarei envolvido no estudo?

You and your baby will be followed from the time you enroll until your baby is 12 months old.

Who can enrol me in the study?

Your doctor can enrol you, or in some places, you might be able to enrol yourself directly.

Como saber mais

Chiesi Clinical Trial

Sempre consulte seu médico ou especialista antes de decidir participar de um estudo.

Interessado em participar?

Registre seu interesse

Compartilhe seus detalhes e a equipe de pesquisa para "Maternal and Postnatal Outcomes Study (MOS): A Global Observ…" entrará em contato com você se você for elegível. Sempre fale com seu médico antes de concordar em participar.

Discussão

Discussão da comunidade

Desenvolvido pelo nosso fórum em community.patient.info. Por favor, seja respeitoso — isto não é um conselho médico.